Comparison of staurosporine and four analogues: their effects on growth, rhodamine 123 retention and binding to P-glycoprotein in multidrug-resistant MCF-7/Adr cells
1996

Effects of Staurosporine and Its Analogues on Multidrug-Resistant Cancer Cells

publication Evidence: moderate

Author Information

Author(s): J Budworth, R Davies, J Malkhandi, TW Gant, DR Ferry, A Gescher

Primary Institution: MRC Toxicology Unit, University of Leicester

Hypothesis

The study investigates the ability of staurosporine and its analogues to reverse multidrug resistance in cancer cells.

Conclusion

Staurosporine and its analogue CGP 41251 are effective in reversing multidrug resistance in cancer cells, with CGP 41251 being the most promising candidate for clinical development.

Supporting Evidence

  • Staurosporine was the most potent cytostatic agent in both MCF-7 and MCF-7/Adr cells.
  • CGP 41251 showed high affinity for P-glycoprotein and was least affected by P-gp-mediated resistance.
  • Reserpine significantly increased the sensitivity of MCF-7/Adr cells to certain staurosporine analogues.

Takeaway

This study shows that certain cancer drugs can help make resistant cancer cells more sensitive to treatment, which could help in fighting cancer better.

Methodology

The study compared the effects of staurosporine and its analogues on cell growth, drug accumulation, and binding to P-glycoprotein in MCF-7/Adr cells.

Limitations

The study does not explore long-term effects or clinical outcomes of the compounds tested.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication